Page last updated: 2024-08-23

bezafibrate and MPTP Neurotoxicity Syndrome

bezafibrate has been researched along with MPTP Neurotoxicity Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bordet, R; Destée, A; Gelé, P; Kreisler, A; Lhermitte, M; Wiart, JF	1

Other Studies

1 other study(ies) available for bezafibrate and MPTP Neurotoxicity Syndrome

Article	Year
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain research, 2007, Mar-02, Volume: 1135, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyl Coenzyme A; Analysis of Variance; Animals; Bezafibrate; Cell Death; Disease Models, Animal; Drug Interactions; Fenofibrate; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; PPAR alpha; Substantia Nigra	2007

Article

Year

Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.

Brain research, 2007, Mar-02, Volume: 1135, Issue:1

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyl Coenzyme A; Analysis of Variance; Animals; Bezafibrate; Cell Death; Disease Models, Animal; Drug Interactions; Fenofibrate; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; PPAR alpha; Substantia Nigra

2007